Posted by AGORACOM-JC
at 5:52 PM on Wednesday, December 8th, 2021
FOBI AI is a global leader in digital wallet pass technology that delivers real-time data analytics and engagement through artificial intelligence to drive customer activation and engagement in stores, stadiums, arenas, hotels and other large venues around the world.
More than just lip service, these are just a sample of the major milestones reached by $FOBI as of the end of November:
293% Increase In First Quarter Revenue
Signed Agreement With Caddle, Canada’s Largest Mobile-First Insights Marketplace App To Target And Engage CPG Brands and Grocery Retailers
Signed Deal to Provide Digital Vaccination and Testing Verification Solution for Sammy Hagar’s Sold Out Shows at The STRAT Hotel, Casino & SkyPod in Las Vegas
Signed CheckVax(TM) Deal With the University of Nevada, Las Vegas for Men’s and Women’s NCAA Basketball Games
By joining Amazon Business, Fobi immediately reaches over 5 million business customers in nine countries: a network that Fobi is very proud to now be included in. Fobi will now generate additional revenue through hardware, products and services sold on Amazon Business.
Rob Anson, Fobi CEO stated : “Acquiring Passworks will not only enable us to further accelerate our business strategy as we consolidate the wallet pass industry, but it will also provide us with direct and immediate access to very valuable customers, with additional operational capacity and provide further immediate revenue. This strategic acquisition of Passworks represents another key step for us in terms of achieving our goal of becoming a global mobile Wallet pass leader.”
Sit back, relax and watch this powerful interview with CEO Rob Anson.
Posted by AGORACOM-JC
at 5:48 PM on Wednesday, December 8th, 2021
HPQ Silicon Resources Inc. (TSX-V: HPQ) is a Canadian producer of Innovative Silicon Solutions, based in Montreal, building a portfolio of unique high-value specialty silicon products needed for the coming RER along with 2 world-renowned technology partners.
high purity silicon metal
spherical silicon nanopowders and nanowires
porous silicon (Si) wafers and porous silicon (Si) powders
HPQ NANO Receives First Order for Spherical Nano Silicon Material from Major Automobile Manufacturer
NDA with at least 2 battery players
Pyrogenesis Canada (a global leader in plasma torch technologies) = 2 reactors
PUREVAP Quartz Reduction Reactors (QRR) to be Commissioned in Q4 2021
an innovative process (patent pending), which will permit the one-step transformation of quartz (SiO 2) into high purity silicon (Si) at reduced costs, energy input, and carbon footprint
PUREVAP TM Nano Silicon Reactor (NSiR ) Through its 100% owned subsidiary, HPQ NANO Silicon Powders Inc., a new proprietary process that can use different purities of silicon (Si) as feedstock, to make a wide range of nano/micro spherical powders of different sizes and nanowires.
EBH 2 first successfully tested prototype model has a clean energy production capacity starting at 1 Megawatt of power that can be produced over 7 days from 2 litres of water; sufficient energy to power a typical three bedroom suburban house.
The tests confirmed that the EBH 2 Green Hydrogen Reactors (EBH 2 GHR) uses low voltage 1 to power electrolysers that generate a H 2 + O 2 gas mixture fuels that can be used to power a generator or any kind of fuel system to produce electricity.
HPQ CEO Bernard Tourillon commented: “Corporations and Governments worldwide strongly believe that Hydrogen can play a significant part in decarbonising our economies, and they are willing to invest billions of dollars to help develop green hydrogen production. EBH2 Systems SA, with their proprietary low-cost electrolyser technology, present HPQ with one of these game changing synergetic opportunities that we simply could not overlook,” Mr. Tourillon, further stated: “We are getting even closer to the point where EBH 2 technology will be validated and when that occurs HPQ will be very well positioned to enter the hydrogen market with a system that can efficiently produce green hydrogen, on demand, which we believe will complement our green silicon materials initiatives needed to meet the demand of the up and coming renewable energy revolution.”
Sit back and watch this power interview with HPQ CEO Bernard Tourillon.
Posted by AGORACOM-JC
at 4:37 PM on Tuesday, November 30th, 2021
HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing high value-added silicon products that are sought after by battery and electric vehicle manufacturers – but nobody has yet delivered – until now.
If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following:
To understand the importance and the implications of this milestone, this excerpt from the press release says it all:
The US patent covers the PUREVAP™ QRR innovative process, which permits the one-step transformation of quartz (SiO 2 ) into high purity silicon metal (from 99.5% to 99.99% Si) at reduced costs, energy input, and carbon footprint. This game-changing advantage means that the PUREVAP™ QRR process not only produces a higher purity silicon material than traditional processes, but it does not require the extremely pure feedstock needed by conventional processes. In fact, the process only requires 4.5 MT of raw material to make 1 MT of Silicon, versus the 6 MT required by conventional processes, a 25% reduction which potentially allows a 20% cash cost advantage versus the lowest cost traditional Silicon producer . Furthermore, as part of our ongoing strategy of protecting and strengthening the PUREVAP™ Intellectual Property Portfolio, a second patent application, focusing on a new and novel process was filed in 2019 and is presently advancing through the process.
Bernard Tourillon, President and CEO of HPQ commented,
“HPQ has been at the forefront of Low-Cost Green Silicon innovation developments since 2015, and getting this U.S. patent approval, combined with the ongoing commissioning of the GEN3 PUREVAP™ QRR pilot plant , has occurred at an opportune time, as demand continues to rise and bottlenecks we had foreseen are now occurring in the silicon supply chain. With ESG principles playing an active role in materials sourcing, the world is more aware of the difficulty of securing the ESG compliant Silicon needed to meet its renewable energy goals. The reality of chronic underinvestment in new technologies combined with the offshoring of Silicon production capacity, has created a massive opportunity for HPQ and its PUREVAP™ QRR patented process, as we are the only company to bring to market a new process to make Silicon that is perfectly suited to the new demands and realities of the Silicon market
Watch this great interview with $HPQ CEO Bernard Tourillon.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Paul Thielking. Paul is a psychiatrist, zen practitioner, and Chief Scientific Officer at Novamind. They discuss healthcare provider burnout and other unique challenges of being in the helping/healing professions.
We are pleased to announce that we have been included in the AdvisorShares Psychedelics ETF trading on the NYSE under the ticker “PSIL” (the “ETF”).
PSIL is the first U.S.-listed, actively managed exchange traded fund to deliver dedicated investment exposure to psychedelics. PSIL seeks long-term capital appreciation by investing in the rapidly evolving psychedelics space, offering exposure to companies which the ETF’s portfolio manager views as leading the way in this nascent industry. The ETF currently includes 22 psychedelics companies.
“The inclusion of Novamind in the AdvisorShares Psychedelics ETF is an important achievement for our Company,” commented Yaron Conforti, CEO and Director of Novamind. “Our clinics and clinical research sites are growing rapidly, and we are pleased to be recognized as a leading company in the emerging psychedelics sector.”
Additional information on the ETF can be found here.
Novamind to be featured in panel discussion on the disruptive potential of psychedelic medicine in mental healthcare
We will participate in the Benzinga Healthcare Small Cap Conference taking place virtually on September 29-30, 2021.
Novamind’s CEO and Director, Yaron Conforti, will join a panel of industry leaders for a discussion titled, “Addressing Mental Health through Emerging Therapies” on Thursday, September 30 at 12:35 PM EST.
Following the panel, from 1:15 PM to 1:30 PM EST, Mr. Conforti will deliver a presentation to update investors on the Company’s rapidly growing network of psychiatry clinics and clinical research sites focused on psychedelic medicine. A short Q&A session will follow.
We are pleased to announce that our common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the U.S.
The DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered ‘DTC eligible’. This electronic method of clearing securities speeds up the receipt of stock and cash and accelerates the settlement process for investors and brokers.
“We are pleased to have become DTC eligible. Investors will benefit from the accelerated settlement process and ability to trade Novamind shares through a wide range of U.S. brokerage firms,” said Yaron Conforti, Chief Executive Officer and Director of Novamind. “This is an important step towards increased liquidity for our stock and building a strong presence for Novamind in the U.S. capital markets.”
A recap of some of the most promising psychedelic drugs for mental health and some of the trailblazers paving the way for the psychedelic revolution. “Sleep, exercise, therapy and antidepressants are some of the top remedies prescribed to assist the 1 in 4 Americans who struggle with mental health issues. But while these are all critical and effective tools, are they enough?”
Novamind’s business model was structured to be drug agnostic. We want to be able to provide the best possible therapies for our clients, regardless of what therapies they end up needing. It’s why we’re a champion for increasing access to all psychedelics. In this article, Shayla Love covers how those interested in psychedelics are learning to work together for the greater good.
Posted by AGORACOM-JC
at 4:07 PM on Tuesday, September 21st, 2021
Kidoz (KIDZ: TSXV) owns the biggest mobile advertising platform for kids and families. How big? There are almost 4,000 apps around the world using Kidoz, reaching over 300 MILLION kids. The company works with top brands, including Disney, McDonald’s, Hasbro, and Lego, and is a trusted partner of Apple and Google.
We sat down with Kidoz Inc. Co-CEOs Jason Williams & Eldad Ben Tora to discuss the entrance into lucrative teens and parents segment of soon to be $400 BILLION Mobile Ad Market.
We discuss:
New markets
Anticipated growth
Agencies that have already booked
+more
Q2 2021 highlights include:
Total Revenue of $2,177,505 – growth of 196% compared to Q2 2020 Total Revenue of $736,827.
AdTech revenue of $2,120,500 – growth of 247% compared to Q2 2020 AdTech Revenue $611,709.
Gross Profit of $1,024,333 – growth of 214% compared to Q2 2020 Gross Profit of $325,769.
EBITDA of $48,079 a 124% improvement from an EBITDA loss of ($197,057) in Q2 2020.
Sit back, relax and watch this powerful interview.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by returning guest, Vhari Macbeth to discuss psycholytic ketamine-assisted psychotherapy (KAP).
We are pleased to announce that our wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a clinical trial sponsored by Karuna Therapeutics, Inc., a clinical-stage neuroscience biopharmaceutical company
The phase III study will evaluate the investigational therapy KarXT for the treatment of schizophrenia, a serious and potentially disabling condition affecting approximately 20 million people worldwide.
Dr. Reid Robison, Novamind’s Chief Medical Officer and Principal Investigator at CCR said, “We need more innovation in this field and I’m hopeful to see compounds like KarXT that have new ways of acting on the brain and the potential for improved efficacy and side effect profiles.”
As psychedelics continue to break free from the stigma surrounding them, more and more people are seeing the promise these drugs have in changing the way we treat mental health. “Recent trials are showing that psychedelics are proving not only successful but also incredibly effective when stacked up against traditional forms of treatment, with one recent trial reporting that they are up to four times more effective than antidepressants.”
In a big step forward for psychedelic research, the DEA is set to increase limits for psilocybin. From the DEA: “DEA firmly believes in supporting regulated research of schedule I controlled substances.” We look forward to increased research and have a dedicated psychedelic contract research organization (CRO) in Cedar Clinical Research, capable of studying promising new treatments.
Posted by AGORACOM-JC
at 1:06 PM on Thursday, September 16th, 2021
PyroGenesis $PYR is the world leader in the development of advanced plasma processes and products. In short, their plasma torch technology has been the foundation of multiple successful applications around the world that significantly reduce both greenhouse gases and costs of doing business for some of the world’s biggest companies in these following verticals:
Ultra High-Tech 3D Printing (Additive Manufacturing)
Iron Ore Pelletization
Aluminum Smelters Recovery Of Dross
High-Purity Silicon For EV Batteries
….. Military Where Their Tech Sits On 4 US Aircraft Carriers.
Today’s $6 Million Plasma Torch Order Represents 4 Torches From Major Iron Ore Pelletizer Client “B”
“B” expects next orders to be for 130 torches
NPV estimate per torch is now $7M = $910,000,000
Client “A” has already requested a cost estimate for 36 torches
Discussions with Client “C” and many others are also taking place
HOW BIG IS THE OPPORTUNITY?
“The total world pellet production of 400 million metric tonnes of pellets represents a potential market for torch sales in excess of $10B worldwide. For reference, 40 million tonnes of CO 2 represent the combined yearly emissions of 8.7 million US passenger vehicles”
Posted by AGORACOM
at 10:06 PM on Saturday, September 11th, 2021
Fabled Silver Gold (FCO TSXV) ( FBSGF: OTC ) controls 100% of the Santa Maria mine gold and silver property in Mexico.
It is a high grade silver gold property that is situated right in the middle of the Mexican Epithermal silver gold belt that has reportedly produced more silver than any other equivalent area in the entire planet.
To say it’s a mining friendly jurisdiction is an understatement.
Multiple major operators are in the vicinity and Santa Maria already has a silver equivalent 43-101 of 3.2m ounces, but is adding to that not only in tonnage, but in grade. High grade; and that only improves a future 43-101.
High grade mines pay back Capital costs faster, making them economic and profitable.
Check out these intercepts from the last 4 press releases that include not only high grade silver but a new gold discovery as well:
Aug 17: New Gold System, Hits Lower Feeder, which Returns 580.01 g/t Silver Eq, PLUS 19.90% Lead, 5.18% Zinc and 1.29% Copper
Aug 23rd: Intercepts Gold Bearing Sheeted Vein Structure Over A True Width of 150 Meters
Sept 1st: New High Grade Vein Breccia Outside Santa Maria Structure Boundaries, with Grades High As 1,072.73 g/t Ag Eq and..
Sept: 8th: Fabled Hits Supergene Quartz Breccia Over 1.35 Meters Grading 689.56 g/t Ag Eq
Fabled is intent on proving Santa Maria is bigger and of potentially higher grade than the market understands, and is well on its way. Grade is king an the mines with the best grade get developed first.
Santa Maria is already a proven past producer, the development progress made by Fabled is only increasing the potential re-development, but with potential better economics. Sit back and enjoy as Peter Hawley President & CEO explains the importance of how high grade intercepts improve a mines chance of being developed.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Hannah Cross to discuss how psychedelic-assisted psychotherapy is used to treat trauma.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss how ketamine-assisted psychotherapy is used to treat eating disorders
We pleased to announce our common shares have been approved for trading under the ticker symbol “NVMDF” on the OTCQB® Venture Market, a U.S. trading platform operated by the OTC Markets Group, Inc.
“With this listing, we look forward to expanding Novamind’s presence in the U.S. and deepening our relationships with a broad base of institutional and retail investors.” said Yaron Conforti, CEO and Director.
CEO and Director, Yaron Conforti, will present the Company’s business model focused on growing a national network of psychiatry clinics and clinical research sites to rapidly scale access to psychedelic medicine.
Learn more about the Conference and register to schedule a one-on-one meeting with Novamind’s management here.
BBC Future covers the experience, culture and future of psychedelics and “what might follow if psychedelics become mainstream.” It’s a popular theme in this week’s roundup: what the world will look like after the psychedelic revolution. “Psychedelics offer something that few other things can: an experience well beyond what our everyday reality could conceive or expect.” With such life changing drugs and therapies becoming available, there’s no doubt the future will look a lot different.
This article delivers more positive news about ketamine and esketamine, which we currently use in our Cedar Psychiatry clinics. Learn more about how we use these powerful drugs here. “Use of ketamine and esketamine for their antidepressant effects does not seem to have harmful neurocognitive effects in individuals with treatment-resistant depression, according to a review published online Aug. 5 in the Harvard Review of Psychiatry.”
Rick Doblin and Jennifer Ouyang Altman lay out the potential risks of not having standardized psychedelic education for providers. It’s a problem that will arise as psychedelics continue to move into the mainstream. It’s one reason why education is such a big component of our mission to increase access to psychedelic medicine. On the Psychedelic Therapy Frontiers podcast, we cover topics across the spectrum from trip-sitting to treating trauma with psychedelic-assisted psychotherapy. Another way we’re helping address this issue is by creating psychedelic treatment protocols, sharing best-in-class techniques and procedures with the wider population. Learn more here.
Posted by AGORACOM-JC
at 4:40 PM on Wednesday, August 25th, 2021
Alejandro Antalich, CEO of Biomind. “We, both, are driven by innovation. At Biomind, our objective is to change the course of medicine by assisting doctors in potentially saving more lives and providing a better quality of life to millions of people suffering from addiction, chronic pain, depression, anxiety, and other mental health disorders.
Biomind Labs is Developing the next generation of medicines for the 21st century … the pharmaceutical side of psychedelics
THE PROBLEM
● Depression and anxiety cost the global economy US$ 1 trillion each year
~ 20% of the world’s children and adolescents have a mental health condition
Suicide is the second leading cause of death among 15-29 year-olds
13% rise in mental health conditions & substance use disorders in last decade (to 2017)
Mental health conditions now cause 1 in 5 years lived with disability
#Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety and depression amongst other things
More than 80% of the global population prefers natural products as sources of new drug candidates …
and that is good because Biomind’s vertical integration approach – Transforming natural psychotropic compounds into pharmaceuticals – creating drug therapies that harness the medicinal power of natural psychedelic compounds
1 indication is already in Phase 2 … 3 indications in Phase 2 by end 2021 … 3 in Phase 3 by end 2022.
Sit back, relax and watch this powerful interview with Alejandro Antalich, Chief Executive Officer of Biomind Labs.
